VYNE Therapeutics Inc VYNE beats Q4 2025 EPS expectations significantly yet shares edge slightly lower in todays trading Is Linkage LGCB stock worth committing funds to Avalanches 20260418 Why Lunai Bioworks LNAI might be the best kept secret in the market At Lows 20260508 EVGN Evogene Ltd Ordinary Shares posts far wider Q4 2025 per share loss than analyst estimates amid ongoing operational headwinds